Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting
Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients ...
Domain Therapeutics to Present Data on its GPCR Lead Programs at AACR Annual Meeting 2025
Domain Therapeutics ("Domain" or "the Company"), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for patients, today announces that it will be presenting new ...
Experimental women's cancer drug boosts survival rates in notable study
A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.